Gene Expression of Tumor Necrosis Factor-Alpha in Etanercept-Treated Rheumatoid Arthritis Patients

Aseel S. Mahmood, Abdul-Kareem A. Al-Kazaz, Ali H. Ad'hiah, Khadier K. Mayouf
2017 Journal of Biosciences and Medicines  
Fifty-one rheumatoid arthritis (RA) patients were enrolled to assess the gene expression of tumor necrosis factor-alpha (TNF-α) by reverse transcription quantitative polymerase chain reaction (qRT-PCR) in etanercept-treated RA patients, with some emphasis on clinical and biological markers of disease. The results revealed that the ∆Ct mean range in total, male and female RA patients and controls was 1.286 ± 1.226 -4.023 ± 0.856 and the differences were not. Laboratory and clinical findings in
more » ... bgroups of patients also showed no significant variations in the distribution of 2 −∆∆Ct means, with the exception of anti-cyclic citrullinated peptide (ACCP) antibodies. The lowest expression was observed in moderate positive patients (1.566 ± 1.104) compared to low and high positive patients (4.061 ± 1.366 and 9.668 ± 3.518, respectively) for ACCP antibodies, and the difference was significant (p = 0.043). Inspecting the 2 −∆∆Ct means in duration of disease and gender revealed that male patients recorded a lower mean than female patients (0.827 ± 0.550 vs. 4.143 ± 1.317) at <5 years disease duration, while at >10 years duration of disease, female patients showed a lower mean than male patients (1.242 ± 0.372 vs. 5.607 ± 3.334). However, both differences were not significant. It is concluded that etanercept was effective in normalizing the TNF gene expression, but variations that were related to gender, duration of disease and some biological markers of disease, were observed.
doi:10.4236/jbm.2017.59001 fatcat:upg3d56gonec3o6wnroobu2jfu